Pharmaceutical News
795 views | +0 today
Follow
 
Scooped by OMP Digital
onto Pharmaceutical News
Scoop.it!

Era of mobile health tracking definitively arrives, Samsung Galaxy S4 & accessories focuses on mHealth

Era of mobile health tracking definitively arrives, Samsung Galaxy S4 & accessories focuses on mHealth | Pharmaceutical News | Scoop.it
When a company that had over $180 billion in net revenue (more than Apple) for 2012 decides to seriously get into mobile health devices, it's safe to say the age of mobile tracking has definitely arrived.
OMP Digital's insight:

Samsung’s S Health app is a native app the phone comes with the Samsung Galaxy 4 enabling you to input the calories you consume in a day and a slew of other fitness metrics.

 

As Samsung made over $180 billion in net revenue (more than Apple) for 2012 they have decided to seriously get into mobile health devices, with this it’s safe to say the age of mobile tracking to the consumer has definitely arrived.

more...
Ines Di Loreto's curator insight, March 19, 2013 4:41 AM

The first mobile with built in health applications

Sven Awege's curator insight, March 20, 2013 5:37 AM

Come on Apple or Microsoft, show us what you've got!

My guess is MS's HealthVault will be packaged into MS solutions within the next year - they have been soft-launching the service again, even in tough markets such as France.

Your new post is loading...
Your new post is loading...
Scooped by OMP Digital
Scoop.it!

BioConvergence® Presents Case Study on Temperature Controlled Pharmaceutical Products

BioConvergence team members Désirée Valentine and Travis Hudson presented their newest case study (including outcomes of yielding a 99.7 percent excursion-free shipping rate) at the 11th Annual Cold...

OMP Digital's insight:

"There is plenty of evidence that suggests that a product’s temperature (and the associated fluctuations) can have profound impacts on a product’s stability, and therefore, its therapeutic effectiveness,” relates Valentine, Senior Supply Chain Manager at BioConvergence

Read more: http://www.digitaljournal.com/pr/1533113#ixzz2i5AdP7di


BioConvergence is a contract service provider to the life sciences industry, offering outsourcing partnerships for formulation development, testing, production, and supply chain services. Headquartered in Bloomington, Indiana, BioC has over 50 employees with more than four centuries’ worth of combined experience in the pharmaceutical industry. BioC’s unique E-Transparency® System provides transparency and flexibility to its clients, while offering superior, quality-driven outsourcing services. For more information, visit http://www.bioc.us

more...
No comment yet.
Scooped by OMP Digital
Scoop.it!

Beyond Big Data: Smart Data for Driving Scientific Discovery

Beyond Big Data: Smart Data for Driving Scientific Discovery | Pharmaceutical News | Scoop.it
OMP Digital's insight:
A fantastic article on Big Data. Data can both empower as well as overwhelm scientists. The “5 V’s” represent the most common big data challenges facing scientists today: volume, velocity, value, veracity and variety.
more...
No comment yet.
Scooped by OMP Digital
Scoop.it!

The cost of creating a new drug is now $5 Billion! Pushing Big Pharma to change

The cost of creating a new drug is now $5 Billion! Pushing Big Pharma to change | Pharmaceutical News | Scoop.it
Susan Desmond-Hellmann There's one factor that, as much as anything else, determines how many medicines are invented, what diseases they treat, and, to an extent, what price patients must pay for them: the cost of inventing and developing a new drug,...
OMP Digital's insight:

From within the article, big pharmaceutical companies as we all know spend big!


Within R+D there is a clear winner: Bristol-Myers focus on understanding human genetics and using the immune system as a weapon against cancer. 


What we would like to make you aware of though is that for the so called smaller pharma companies who are hoping to get a single drug to market, they can expect to have spent $350 million before the medicine is available for sale. 


Which leads to the large costing prices stated above as dozens of drug projects fail and have to be tweaked before aproval. 

more...
June García's curator insight, November 23, 2013 11:19 AM

El desarrollo de un nuevo fármaco es muy largo y muy costoso, por lo que solo las grandes farmacéuticas van a poder llevarlo desde su inicio hasta la venta. Estas farmacéuticas investigan en enfermedades muy comunes, ya que es donde luego van a obtener un gran beneficio. El problema es que muchas enfermedades, sobre todo tercermundistas, las llamadas enfermedades olvidadas, no se investigan, ya que no van a producir un beneficio a la farmacéutica y, por tanto, la gente muere.

Scooped by OMP Digital
Scoop.it!

Can you imagine the #Papertab in your local hospital

Can you imagine the #Papertab in your local hospital | Pharmaceutical News | Scoop.it
V3 has a closer look at paper thin tablet innovation
OMP Digital's insight:

We all know the iPad is the favoured tablet within the healthcare and pharmaceutical world, but what if a bendy paper tablets were the next best thing? Ensuring the replacement of paper, it really offers a compelling insight into the future of tablet computing. 

more...
No comment yet.
Scooped by OMP Digital
Scoop.it!

FDA studying possible cancer risk of anti-diabetes drugs

FDA studying possible cancer risk of anti-diabetes drugs | Pharmaceutical News | Scoop.it
The US Food and Drug Administration said Thursday it was reviewing results of unpublished studies hinting at higher risks of ulcers and pancreatic cancer for users of certain anti-diabetes drugs
OMP Digital's insight:

FDA review unpublished studies that hints at pancreatic cancer on certain anti-diabetic drugs. All samples were taken from deceased diabetics that had used medicine to mimic incretin hormones, which would release insulin in response to a meal. 

 

There has been no conclusion ariund the safety risks, however have issues messages to the public and HCP's.

more...
No comment yet.
Scooped by OMP Digital
Scoop.it!

Scientists find HIV 'functional cure' possible with early treatment

Scientists find HIV 'functional cure' possible with early treatment | Pharmaceutical News | Scoop.it
French researchers find treating with anti-Aids drugs soon after infection could control virus in some patients
OMP Digital's insight:

A closely matched functional cure has been found by French researchers by swiftly treating a sample of 14 patients with HIV drugs, showing no signs of the virus after 7 years. This is fabulous news for the 34 million people currently suffering with HIV and brings hope to so many in both developing and developed countries.   

more...
No comment yet.
Scooped by OMP Digital
Scoop.it!

U.K. physicians join up with pharma in doc-payment pledge

OMP Digital's insight:

Will U.K. drugmakers be the next to shine a light on payments to doctors? A leading physicians group and the Association of the British Pharmaceutical Industry are promising new disclosures. What form those disclosures will take remains to be seen.

more...
No comment yet.
Scooped by OMP Digital
Scoop.it!

Increasing demand for online services from pharma

Increasing demand for online services from pharma | Pharmaceutical News | Scoop.it
OMP Digital - www.ompdigital.com
OMP Digital's insight:

Patients, consultants and doctors are interested in patient support programmes from pharma, and don't necessarily mind registering for access. 

more...
No comment yet.
Scooped by OMP Digital
Scoop.it!

Watson completes acquisition of Belgium-based Uteron Pharma

Watson completes acquisition of Belgium-based Uteron Pharma | Pharmaceutical News | Scoop.it
Watson completes acquisition of Belgium-based Uteron Pharma
OMP Digital's insight:

Watson Pharmaceuticals, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products, has completed the acquisition of Belgium-based Uteron Pharma SA for $150 million in cash up front, and up to $155 million in potential future milestone payments.  

more...
No comment yet.
Scooped by OMP Digital
Scoop.it!

Abiraterone acetate approved in the EU for use in the treatment of metastatic castration-resistant prostate cancer before chemotherapy

Abiraterone acetate approved in the EU for use in the treatment of metastatic castration-resistant prostate cancer before chemotherapy | Pharmaceutical News | Scoop.it
OMP Digital's insight:

Janssen-Cilag International NV (Janssen) announced that the European Commission (EC) has approved an extension to the license of the oral, once-daily medication abiraterone acetate.

more...
No comment yet.
Scooped by OMP Digital
Scoop.it!

Can exercise aid war on dementia?

Can exercise aid war on dementia? | Pharmaceutical News | Scoop.it
VOLUNTEERS are being sought for a major study into the link between exercise and dementia. People aged 60 and over are being invited to take part in  four-week or 12-week programmes of exercise or mental tasks by researchers.
more...
No comment yet.
Scooped by OMP Digital
Scoop.it!

Flu vaccines evolution improves with the investment of US government.

Flu vaccines evolution improves with the investment of US government. | Pharmaceutical News | Scoop.it
Fighting the flu may soon get easier. As early as next year, more modern and more effective vaccines will hit the market, thanks to investments by the U.S. government and pharmaceutical companies.
OMP Digital's insight:

Experts say a universal flu vaccine could take between 8 - 10 years away from now, making annual flu jabs obsolete.

more...
No comment yet.
Scooped by OMP Digital
Scoop.it!

Indian pharmaceutical market set to for annual growth of 14-17% over 2012-2016

Indian pharmaceutical market set to for annual growth of 14-17% over 2012-2016 | Pharmaceutical News | Scoop.it
The Indian market is now among the top five pharmaceutical emerging, or ‘pharmerging’ , markets.
OMP Digital's insight:

Indian market among the top five pharmaceutical emerging markets

more...
No comment yet.
Scooped by OMP Digital
Scoop.it!

Pharma welcomes UK antimicrobial strategy

Pharma welcomes UK antimicrobial strategy | Pharmaceutical News | Scoop.it
This was discussed at the #rpsconf. Pharma buy into Govt antimicrobial strategy @rpharms @PJOnline_News http://t.co/wngpqozXN7
more...
No comment yet.
Scooped by OMP Digital
Scoop.it!

Oncology lucrative lifesavers

Oncology lucrative lifesavers | Pharmaceutical News | Scoop.it
NEW weapons are emerging in the war on cancer. That is good news not just for patients but also for drug companies. The biggest ones, faced with falling sales as...
OMP Digital's insight:

Over time the understanding of cancer is evolvingsurgery, radiation and chemotherapy were the methods used in the 20th century. Immunotherapy and genomics are aiding research scientists target specific mutations that promote cancer, resulting in good news for the patients and pharma companies. 

more...
No comment yet.
Scooped by OMP Digital
Scoop.it!

Graphic Medicine | Exploring the interaction between the medium of comics and the discourse of healthcare.

Graphic Medicine | Exploring the interaction between the medium of comics and the discourse of healthcare. | Pharmaceutical News | Scoop.it
Graphic Medicine is the definitive blog in the realm of comics and medicine. Find comic reviews, articles, conferences, and our podcast.
more...
No comment yet.
Scooped by OMP Digital
Scoop.it!

Humetrix aims to bring iBlueButton to the UK NHS

Humetrix aims to bring iBlueButton to the UK NHS | Pharmaceutical News | Scoop.it
OMP Digital's insight:

Humetrix aim to demonstrate the benefits of technology for a health information medical exchange app, ending the current issue of readily available medical records. 

more...
No comment yet.
Scooped by OMP Digital
Scoop.it!

Era of mobile health tracking definitively arrives, Samsung Galaxy S4 & accessories focuses on mHealth

Era of mobile health tracking definitively arrives, Samsung Galaxy S4 & accessories focuses on mHealth | Pharmaceutical News | Scoop.it
When a company that had over $180 billion in net revenue (more than Apple) for 2012 decides to seriously get into mobile health devices, it's safe to say the age of mobile tracking has definitely arrived.
OMP Digital's insight:

Samsung’s S Health app is a native app the phone comes with the Samsung Galaxy 4 enabling you to input the calories you consume in a day and a slew of other fitness metrics.

 

As Samsung made over $180 billion in net revenue (more than Apple) for 2012 they have decided to seriously get into mobile health devices, with this it’s safe to say the age of mobile tracking to the consumer has definitely arrived.

more...
Ines Di Loreto's curator insight, March 19, 2013 4:41 AM

The first mobile with built in health applications

Sven Awege's curator insight, March 20, 2013 5:37 AM

Come on Apple or Microsoft, show us what you've got!

My guess is MS's HealthVault will be packaged into MS solutions within the next year - they have been soft-launching the service again, even in tough markets such as France.

Scooped by OMP Digital
Scoop.it!

Pharmaceutical sector grows 22% to defy recession

Pharmaceutical sector grows 22% to defy recession | Pharmaceutical News | Scoop.it
The services and pharmaceutical sectors are helping pull the Northern Ireland economy out of recession, according to latest government statistics.
more...
No comment yet.
Scooped by OMP Digital
Scoop.it!

Conference highlights for pharma

Conference highlights for pharma | Pharmaceutical News | Scoop.it
OMP Digital - www.ompdigital.com
OMP Digital's insight:
Summary reports on meeting abstracts and evolving therapiesArticles about the latest treatment optionsKOL video interviews from the events top speakersGroup Panel discussions on the most talked about topicsAttendee sound bites to capture their reactions on the day
more...
No comment yet.
Scooped by OMP Digital
Scoop.it!

Sanofi US joins NBA for diabetes awareness drive

Sanofi US joins NBA for diabetes awareness drive | Pharmaceutical News | Scoop.it
OMP Digital's insight:

Sanofi US and the American Diabetes Association have teamed up with major US basketball leagues to help increase public awareness of type 2 diabetes.

more...
No comment yet.
Scooped by OMP Digital
Scoop.it!

Pharma MNCs use RTI law to protect market for patented drugs & delay entry of generics

Pharma MNCs use RTI law to protect market for patented drugs & delay entry of generics | Pharmaceutical News | Scoop.it
MNCs are using such information to sue generic firms even at a stage when their marketing approval is still pending or during the few months' window between the grant of approval and the actual product launch.
more...
No comment yet.
Scooped by OMP Digital
Scoop.it!

Allergan to acquire 100% share of MAP Pharmaceuticals at a price of $25 per share

Allergan to acquire 100% share of MAP Pharmaceuticals at a price of $25 per share | Pharmaceutical News | Scoop.it
Allergan, Inc. and MAP Pharmaceuticals, Inc. today jointly announced that they have entered into a definitive merger agreement whereby Allergan will acquire 100% of the shares of MAP Pharmaceuticals for a price of $25.00 per share.
OMP Digital's insight:

The transaction, which has been unanimously approved by the boards of directors of both companies, will be accomplished pursuant to a cash tender offer followed by a second step merger. The per share cash offer price represents a 60% premium over MAP’s closing stock price on the Nasdaq Stock Market of $15.58 on January 22, 2013, and represents a total equity value of approximately $958 million, on a fully-diluted basis. The acquisition is expected to close late in the first quarter or in the second quarter of 2013.

more...
No comment yet.
Scooped by OMP Digital
Scoop.it!

FDA clears combined oral contraceptive medication - product marketing begins soon

FDA clears combined oral contraceptive medication - product marketing begins soon | Pharmaceutical News | Scoop.it
OMP Digital's insight:

The US FDA has issued marketing approval for Lupin Pharmaceuticals' Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.1mg / 0.02mg, the combined oral contraceptive.

more...
No comment yet.